Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal against Eli Lilly’s Tirzepatide

view original post

Novo Nordisk’s shares fell over 14% following the disappointing results of its CagriSema drug trial against Eli Lilly’s Tirzepatide. The company’s market outlook is worsened by this setback, with …